Khalaji Amirmohammad, Behnoush Amir Hossein, Saeedian Behrad, Khanmohammadi Shaghayegh, Shokri Varniab Zahra, Peiman Soheil
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Diabetol Metab Syndr. 2023 May 16;15(1):102. doi: 10.1186/s13098-023-01076-z.
Diabetes is one of the chronic conditions with a high burden all around the world. Macrovascular and microvascular involvement are among the common mechanisms by which diabetes can impact patients' lives. Endocan as an inflammatory endothelial biomarker has been shown to increase in several communicable and non-communicable diseases. Herein, we aim to investigate the role of endocan as a biomarker in diabetes as a systematic review and meta-analysis.
International databases, including PubMed, Web of Science, Scopus, and Embase were searched for relevant studies assessing blood endocan in diabetic patients. Estimation of the standardized mean difference (SMD) and 95% confidence interval (CI) for comparison of circulating endocan levels between diabetic patients and non-diabetic controls were conducted through random-effect meta-analysis.
Totally, 24 studies were included, assessing 3354 cases with a mean age of 57.4 ± 8.4 years. Meta-analysis indicated that serum endocan levels were significantly higher in diabetic patients in comparison with healthy controls (SMD 1.00, 95% CI 0.81 to 1.19, p-value < 0.01). Moreover, in the analysis of studies with only type-2 diabetes, the same result showing higher endocan was obtained (SMD 1.01, 95% CI 0.78 to 1.24, p-value < 0.01). Higher endocan levels were also reported in chronic diabetes complications such as diabetic retinopathy, diabetic kidney disease, and peripheral neuropathy.
Based on our study's findings, endocan levels are increased in diabetes, however, further studies are needed for assessing this association. In addition, higher endocan levels were detected in chronic complications of diabetes. This can help researchers and clinicians in recognizing disease endothelial dysfunction and potential complications.
糖尿病是全球负担较重的慢性病之一。大血管和微血管受累是糖尿病影响患者生活的常见机制。内皮糖蛋白作为一种炎症性内皮生物标志物，已证实在多种传染病和非传染病中会升高。在此，我们旨在通过系统评价和荟萃分析来研究内皮糖蛋白作为生物标志物在糖尿病中的作用。
检索国际数据库，包括PubMed、科学网、Scopus和Embase，以查找评估糖尿病患者血液中内皮糖蛋白的相关研究。通过随机效应荟萃分析，估计标准化均数差（SMD）和95%置信区间（CI），以比较糖尿病患者和非糖尿病对照者循环内皮糖蛋白水平。
共纳入24项研究，评估了3354例患者，平均年龄为57.4±8.4岁。荟萃分析表明，与健康对照相比，糖尿病患者的血清内皮糖蛋白水平显著更高（SMD 1.00，95%CI 0.81至1.19，p值<0.01）。此外，在仅针对2型糖尿病的研究分析中，也得到了内皮糖蛋白水平更高的相同结果（SMD 1.01，95%CI 0.78至1.24，p值<0.01）。在糖尿病视网膜病变、糖尿病肾病和周围神经病变等慢性糖尿病并发症中，也报告了较高的内皮糖蛋白水平。
基于我们的研究结果，糖尿病患者的内皮糖蛋白水平升高，然而，需要进一步研究来评估这种关联。此外，在糖尿病慢性并发症中检测到较高的内皮糖蛋白水平。这有助于研究人员和临床医生认识疾病的内皮功能障碍和潜在并发症。
